Trial · NCT00256776
MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation
NCT00256776, Phase 3, Terminated, European Society for Blood and Marrow Transplantation; results first posted 2021-10-18
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation. Trials, record NCT00256776. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00256776
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation
- NCT number
- NCT00256776
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 269 participants, actual
- Lead sponsor
- European Society for Blood and Marrow Transplantation
- Conditions
- Multiple Myeloma
- Interventions
- Velcade (Bortezomib), Thalidomide, Dexamethasone
- First posted
- 2005-11-22
- Last updated
- 2021-10-18
- Results first posted
- 2021-10-18
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Median Time to Progression (TTP) | 3 year | |
| Secondary | Progression Free Survival | 3 year | |
| Secondary | Overall Survival (Interval Between Date of Randomization and Death From Any Cause | 1 year | |
| Secondary | Response Rate (Proportion of Subjects Who Achieve Complete, Partial, or Minimal Response) | 1 year |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Median Time to Progression (TTP) | 3 year | months | MEDIAN | |
| SECONDARY | Progression Free Survival | 3 year | months | MEDIAN | |
| SECONDARY | Overall Survival (Interval Between Date of Randomization and Death From Any Cause | 1 year | |||
| SECONDARY | Response Rate (Proportion of Subjects Who Achieve Complete, Partial, or Minimal Response) | 1 year |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Median Time to Progression (TTP) | Thal + Dex + Velcade | 19.5 | 95% Confidence Interval 16.3 to 22.7 | months | |
| Median Time to Progression (TTP) | Thal + Dex | 13.8 | 95% Confidence Interval 10.0 to 16.4 | months | |
| Progression Free Survival | Thal + Dex + Velcade | 18.3 | 95% Confidence Interval 15.5 to 20.6 | months | |
| Progression Free Survival | Thal + Dex | 13.6 | 95% Confidence Interval 9.9 to 16.1 | months |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Thal + Dex + Velcade | 135 | |
| Overall Study | STARTED | Thal + Dex | 134 | |
| Overall Study | COMPLETED | Thal + Dex + Velcade | 52 | |
| Overall Study | COMPLETED | Thal + Dex | 54 | |
| Overall Study | NOT COMPLETED | Thal + Dex + Velcade | 83 | |
| Overall Study | NOT COMPLETED | Thal + Dex | 80 |
Source ClinicalTrials.gov
Adverse events28
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Neuropathy | Nervous system disorders | Thal + Dex + Velcade | 3 | 135 | 3 |
| serious | Neuropathy | Nervous system disorders | Thal + Dex | 0 | 134 | 0 |
| serious | Renal Failure | Renal and urinary disorders | Thal + Dex + Velcade | 3 | 135 | 3 |
| serious | Renal Failure | Renal and urinary disorders | Thal + Dex | 1 | 134 | 1 |
| serious | Pancreatitis | Hepatobiliary disorders | Thal + Dex + Velcade | 1 | 135 | 1 |
| serious | Pancreatitis | Hepatobiliary disorders | Thal + Dex | 0 | 134 | 0 |
| serious | Respiratory Distress | Respiratory, thoracic and mediastinal disorders | Thal + Dex + Velcade | 1 | 135 | 1 |
| serious | Respiratory Distress | Respiratory, thoracic and mediastinal disorders | Thal + Dex | 0 | 134 | 0 |
| serious | Lung Carcinoma | Reproductive system and breast disorders | Thal + Dex + Velcade | 0 | 135 | 0 |
| serious | Lung Carcinoma | Reproductive system and breast disorders | Thal + Dex | 2 | 134 | 2 |
1 to 10 of 28Source ClinicalTrials.gov
See all 28 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Thal + Dex + Velcade | ||
| Total, all-cause mortality | Thal + Dex | ||
| Total, other adverse events | Thal + Dex + Velcade | 0 | 135 |
| Total, other adverse events | Thal + Dex | 0 | 134 |
| Total, serious adverse events | Thal + Dex + Velcade | 58 | 135 |
| Total, serious adverse events | Thal + Dex | 45 | 134 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Thal + Dex + Velcade vs Thal + Dex: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00256776
GET https://conductscience.org/api/trials/v1/NCT00256776/events?page=2